Abbott eyes Humira tweaks on way to No. 1

Abbott Laboratories has big plans for new forms of Humira, the Wall Street Journal reports, including a long-acting, one-dose-a-month version, in an attempt to keep growing a franchise that is set to top the drug-sales charts beginning next year. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.